[PDF] Top 20 Advances of CD19-directed chimeric antigen receptor-modified T cells in refractory/relapsed acute lymphoblastic leukemia
Has 10000 "Advances of CD19-directed chimeric antigen receptor-modified T cells in refractory/relapsed acute lymphoblastic leukemia" found on our website. Below are the top 20 most common "Advances of CD19-directed chimeric antigen receptor-modified T cells in refractory/relapsed acute lymphoblastic leukemia".
Advances of CD19-directed chimeric antigen receptor-modified T cells in refractory/relapsed acute lymphoblastic leukemia
... B-cell acute lymphoblastic leukemia remains to be a significant cause of cancer-associated mor- bidity and mortality for children and ...priority. Chimeric antigen ... See full document
7
Co-infusion of haplo-identical CD19-chimeric antigen receptor T cells and stem cells achieved full donor engraftment in refractory acute lymphoblastic leukemia
... 97.2% CD19+, ...with relapsed and refractory B cell ALL and was the first patient enrolled in this phase I clinical trial ...donor-derived CD19-directed CAR-T cells and ... See full document
6
<p>Delayed remission following sequential infusion of humanized CD19- and CD22-modified CAR-T cells in a patient with relapsed/refractory acute lymphoblastic leukemia and prior exposure to murine-derived CD19-directed CAR-T cells</p>
... initially relapsed very quickly. The B cells returned to normal ...cell antigen was mutated but undetected, and the CAR-T cells could not recognize leukemic ...CAR-CD19 T ... See full document
5
Clinical trials of dual-target CAR T cells, donor-derived CAR T cells, and universal CAR T cells for acute lymphoid leukemia
... pediatric acute lymphoblastic leukemia (ALL) is highly successful with cure rate ap- proaching 80% [1 – ...for refractory and/ or relapsed (R/R) ALL [4 – ...when chimeric ... See full document
11
CTL019 (tisagenlecleucel): CAR-T therapy for relapsed and refractory B-cell acute lymphoblastic leukemia
... with acute lymphoblastic leukemia (ALL) has dramatically improved, but the subgroup of patients with relapsed/refractory ALL still continues to have dismal ...approach, chimeric ... See full document
14
Predominant cerebral cytokine release syndrome in CD19-directed chimeric antigen receptor-modified T cell therapy
... Chimeric antigen receptor-modified (CAR) T cells targeting CD19 (CART19) have shown therapeutical activities in CD19+ ...CAR T cells as a culprit was ... See full document
5
CAR-T “the living drugs”, immune checkpoint inhibitors, and precision medicine: a new era of cancer therapy
... New advances in the design and manufacture of monoclonal antibodies, bispecific T cell engagers, and antibody- drug conjugates make the antibody-directed agents more powerful with less ...for ... See full document
5
CD19 CAR-T cell therapy for relapsed/refractory acute lymphoblastic leukemia: factors affecting toxicities and long-term efficacies
... with relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL) remains dismal even at this day and age [1, ...with CD19+, Philadelphia chromosome (Ph)––negative R/R ALL [11] ... See full document
5
The potential of CAR T therapy for relapsed or refractory pediatric and young adult B-cell ALL
... as chimeric antigen receptor (CAR) T cells, which have revolutionized the treat- ment of pediatric patients with relapsed or refractory B-cell acute ... See full document
12
Third-generation CD28/4-1BB chimeric antigen receptor T cells for chemotherapy relapsed or refractory acute lymphoblastic leukaemia: a non-randomised, open-label phase I trial protocol
... fi t for further investigation of long-term effects of CAR-T ...CAR-T cells may be challenged by residual ele- ments of the immune system from immunocompromised ...human CD19 expression ... See full document
7
CAR-T cells targeting CLL-1 as an approach to treat acute myeloid leukemia
... CLL-1 has been reported to be expressed in myeloid lineage and AML blasts. In order to determine if CLL-1 is an ideal AML target for CAR-T therapy, we first eval- uated CLL-1 surface expression on AML cell lines ... See full document
13
Abstract: Despite advances in the understanding of its molecular pathophysiology, prostate cancer
... the cells that stop ...CAR-T cells outperform their third generation ...(CIK) cells expressing a second generation CAR containing CD28-CD3ζ domains presented higher antitumor efficacy than CIK ... See full document
14
Treating relapsed or refractory Philadelphia chromosome-negative acute lymphoblastic leukemia: liposome-encapsulated vincristine
... lymphocytic leukemia, ALL, and a variety of solid ...In leukemia cell lines, exposure to vincristine from one to 72 hours resulted in a 10 5 -fold ... See full document
10
Current approaches to increase CAR T cell potency in solid tumors: targeting the tumor microenvironment
... particular T-cells engineered to express Chimeric Antigen Receptors (CARs) have demonstrated recent significant clinical efficacy with improvements in patient outcomes for a number of ... See full document
8
Novel immunotherapies for adult patients with B-lineage acute lymphoblastic leukemia
... CAR T cells in B cell malignancy patients who relapsed after allo-HSCT ...derived CD19-redirected virus-specific T cells, in which no evidence of GVHD was reported ...CAR ... See full document
13
A quantitative method for measuring the transfection efficiency of CD19-directed chimeric antigen receptor in target cells
... verified CD19-T vector recombinant plasmid and pCold TF plasmid which contained CspA pro- moter (a cold promoter, used to induce expression at low temperatures) and an ampicillin-resistance gene were di- ... See full document
6
<p>Coexistence Of A Huge Venous Thromboembolism And Bleeding Tendency In Cytokine Release Syndrome During CAR-T Therapy</p>
... tumor cells, therapeutic agents and infectious ...CAR-T cells attacked tumor cells, produced large amounts of cytokines, activated the exogenous coagulation pathway or directly acti- vated ... See full document
6
Rejection of Experimental Hodgkins Lymphoma by T Cells Engineered with a CD19 Chimeric Antigen Receptor
... T cells engineered to express chimeric antigen receptors (CARs) combining an external antibody binding domain with the CD3ζ T cell receptor (TCR) signaling domain for triggering ... See full document
9
Recent advances on blinatumomab for acute lymphoblastic leukemia
... In a phase 2 clinical trial of blinatumomab for R/R B-ALL, a total of 36 patients were enrolled. The CR/CRh rate was 69% (25/36) after the first two cycles. Among the responders, 88% (22/25) achieved a molecular ... See full document
8
Comparison of CAR-T19 and autologous stem cell transplantation for refractory/relapsed non-Hodgkin’s lymphoma
... Our study has several limitations. B-NHL is a group of heterogeneous malignancies consisting of multiple subtypes with different clinical characteristics, prognosis, and responsiveness to certain treatments. Thus, ... See full document
13
Related subjects